[{"arm_notes": "", "treatment_id": null, "treatment_name": "Standard therapy (Control group): Standard therapy.Jusvinza (Experimental group): Standard therapy + JusvinzaStandard therapy: Application of all the measures approved in the MINSAP protocol for the management of patients with Acute Respiratory Distress generated by COVID-19Jusvinza: 1mg or 2mg by intravenous route up to the patient recover the status (how to not show the requiring of oxygen; and none sign or symptoms of acute respiratory failure). If during of treatment patients present impairing the clinical status or measuring related with laboratory parameters; the clinician could increase the dose each 2mg by intravenous route to 12 hours. The obesity patients will be receive 2 mg since initial of treatment.;Peptides;Administration; Intravenous;Jusvinza", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]

[{"arm_notes": "", "treatment_id": 2044, "treatment_name": "Jusvinza", "treatment_type": "Anti-inflammatories", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "", "treatment_id": 2188, "treatment_name": "Standard of care", "treatment_type": "Standard of care", "pharmacological_treatment": "Standard of care"}]